Synthetic Biologics, Inc.

http://www.syntheticbiologics.com/

Last activity: 03.08.2021

Active

Categories: BioTechCauseDevelopmentHealthTechInformationWebsite

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and (2) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), antibiotic-associated diarrhea (AAD) and the emergence of antimicrobial resistance (AMR). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

Twitter Facebook LinkedIn Email

Likes

487

Mentions

Overview

Location

United States, Maryland, Germantown

Employees

11-50

Phone

+1 310-417-4364

Founded date

1986

Mentions in press and media 13

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
May 5, 2021	Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results
Apr 14, 2021	Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
Apr 1, 2021	Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase
Mar 4, 2021	Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results
Dec 22, 2020	Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol
Nov 24, 2020	Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American
Nov 12, 2020	Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors
Sep 17, 2018	Here’s a look at Maryland’s publicly-traded biotech companies	When talk turns to Maryland’s biotech bonafides, the ideas and talent being produced by government institutions like NIH, and research-oriented universities with connected health systems such as Johns Hopkins and University of Maryland are ...
Jun 12, 2017	Seres initiates industry-first pivotal microbiome trial	Seres has long been a leader in the high-buzz microbiome field. In June 2015, it executed the industry’s first-ever initial public offering (IPO), raising an impressive $134 million. It also claimed the ticker symbol MCRB. But it’s not all ...
Jul 19, 2013	What’s special about the 3 biotechs in the top 10 for Q2 venture investments?	But let’s look a little more closely at the those three biotechnology companies and what they say about what is drawing investor attention. Two of the three provide valuable services to other life science companies. The third has a heart fa...
	What’s special about the 3 biotechs in the top 10 for Q2 venture investments?	Cellular engineering, precision medicine, and using G protein-coupled receptors to treat heart failure and other conditions. That’s the focus of the three biotechnology companies that made the top 10 for venture investment deals last quarte...
	Seres initiates industry-first pivotal microbiome trial	Microbiome therapies are now one step closer to the clinic following the initiation of Seres Therapeutics’ Phase 3 clinical trial in patients with C. difficile infections. According to a company statement, this will be the first pivotal tri...

Reviews 0

FAQ about Synthetic Biologics, Inc.

When was Synthetic Biologics, Inc. founded?

Synthetic Biologics, Inc. was founded in 1986.

What has the press written about Synthetic Biologics, Inc.?

Parsers VC has collected 13 articles mentioning Synthetic Biologics, Inc., among them “Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results” (May 5, 2021) and “Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients” (Apr 14, 2021).

Is Synthetic Biologics, Inc. still active?

Yes, Synthetic Biologics, Inc. is active; its latest activity on Parsers VC dates from Aug 3, 2021.